Canadian company Covalon Technologies
Ltd. is expanding into several Middle Eastern countries with Qatar positioned to
benefit from the advanced medical care products firm’s newly established
presence.
Covalon develops and markets next-generation wound care applications
for infection management. The Ontario- based firm recently expanded its
distribution in the Middle East, with Iran and the United Arab Emirates also on the company’s list of potential clients.
“Our success in Saudi Arabia has opened the doors for
Covalon to capture market share in other important countries in the Middle East,” Covalon CEO Brian Pedlar said. “These additional markets have the opportunity
to significantly increase our business in the region.”
Hamad Medical Corporation operates Qatar’s secondary
and tertiary care system comprised of five specialty and three community hospitals. With Hamad’s assistance, Covalon’s signature product, ColActive
Plus Ag, passed a trial period in Qatar’s hospital system with flying colors,
enabling Covalon to advance to the next step.
Now, Covalon has entered an agreement to distribute a full
product line for Qatar’s health care facilities and is completing a similar
process with Abu Dhabi, extending its product availability to primary care
centers as well as blood banks.
Hamed Abbasian, Covalon’s vice president for business development,
described ColActive Plus Ag as highly successful in treating hard-to-heal lesions,
noting that it has been used in Iran since 2011.
“(It) is considered as one of the most efficacious dressings
for the treatment of chronic wounds,” Abbasian said. “We have entered into a
distribution agreement to expand the distribution of our ColActive Plus Ag
product and to provide Covalon’s IV Clear, SurgiClear, and CovaWound (additional) product lines.”
When used together, ColActive and CovaWound promote rapid
closure and healing. Abbasian indicated that the product line will benefit patients in Qatar, which has in the past been a relatively underserved
market.
“With key opinion leaders … supporting the launch of our
infection management and wound care products into the market, we see the
opportunity for all of Covalon’s products to be category leaders,” he said.
